Melanoma with BRAFV600E/K (or other mutations) are sensitive to the targeted therapy because of these specific activating mutations that are not typically found in cSCC [158]; while they can be found in colon cancer [159], it is true that the activation of other pathways such as EGFR are responsible for lack of activity for single agent BRAF targeted therapies. Here, BRAF is linked to melanoma.